Skip to content

19-081 - Efficacy and Safety of TD-1473 in Crohn's Disease

Status: open

A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderately-to-Severely Active Crohn’s Disease

Treatment for Crohn´s Disease

Contact Us Or call 251-660-5555


A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 12 weeks of induction therapy with TD˗1473 in subjects with moderately-to-severely active CD. This study includes 3 phases: Screening, Induction, and Active Treatment Extension (ATE). The Induction phase of the study is a randomized, double blind, placebo controlled, parallel group study evaluating 2 oral dose levels of TD-1473 compared to placebo for 12 weeks in subjects with moderately to-severely active CD. Subjects who complete Induction will continue to receive TD-1473 in the ATE, for up to 48 additional weeks.

Providers Associated With This Trial

Principle Investigator

  • Jack Di PalmaView Profile
    Jack A. Di Palma, M.D.GastroenterologistProgram Director of Division of Gastroenterology; Director of Section of Inflammatory Bowel Diseases; Professor of Internal Medicine

Sub Investigators

This link will open in a new tab or window.